Company / EPS (Diluted)
Serina Therapeutics, Inc. EPS (Diluted) History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$1.51
FY2025
5-year range
-$9.70 / $0.73
FY2021-FY2025
Trend
-306.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
EPS (Diluted) changed -307% YoY in FY2025, a notable deviation from the 5-year average annual change of -698%.
Based on SEC 10-K filings.
-1.51 in FY2025.
Improved from $-9.70 to $-1.51 over the past 2 years.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, eps (diluted) decreased 306.8% year-over-year.
- Peak eps (diluted) was recorded in FY2024.
- Lowest eps (diluted) in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -18.20 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.51 | -306.8% |
| FY2024 | $0.73 | +107.5% |
| FY2023 | -$9.70 | - |
| FY2022 | - | - |
| FY2021 | -$0.29 | +12.1% |
| FY2020 | -$0.33 | -57.1% |
| FY2018 | -$0.21 | - |
As of FY2025 · SEC 10-K Annual Filings · Updated Jun 24, 2026